Evaluation of the Safety and Efficacy of EXPAREL (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty

Trial Profile

Evaluation of the Safety and Efficacy of EXPAREL (Bupivacaine Liposome Injectable Suspension) When Administered Via Infiltration Versus Instillation in Subjects Undergoing Bilateral Augmentation Mammoplasty

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2014

At a glance

  • Drugs Bupivacaine (Primary) ; Bupivacaine (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Pacira Pharmaceuticals
  • Most Recent Events

    • 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Jul 2012 Official Title amended as reported by ClinicalTrials.gov.
    • 28 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top